ZVSA · OTC
Companies at this level ended the following year delisted, bankrupt, restated or silent 9.2% of the time, against 4.0% for companies with a clean record.
Hover or tap a dot to see the filings behind that score.
ZyVersa Therapeutics, Inc. (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 (the “Form 10-Q”) within the prescribed time period without unreasonable effort and expense. The Company requires additional time to complete its management review of the Company’s quarter end consolidated financial statements and related disclosures. The Company currently expects to file the Form 10-Q within the five-day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended. Forward-Looking Statements This Form 12b-25 contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, including statements regarding the Company’s expectations regarding the timing of filing its Form 10-Q on or before the fifth day following its prescribed due date (the “extension deadline”), the consistency of the financial statements in the Form 10-Q with the financial information in the earnings release and the completion of matters necessary to permit filing by the extension deadline. Such forward-looking statements are based on assumptions about many important factors that could cause actual results to differ materially from those in the forward-looking statements, including whether the Company will identify additional errors in previously issued financial statements and other risks identified in the Company’s most recent filing on Form 10-K and other SEC filings, all of which are available on the Company’s website. The Company can provide no assurance that these forward-looking statements will be achieved, and actual results could differ materially from those suggested by such forward-looking statements. The Company does not undertake to update its forward-looking statements unless otherwise required by the federal securities laws
NT 10-Q, filed 2025-11-14 · investigation
ZyVersa Therapeutics, Inc. (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 (the “Form 10-Q”) within the prescribed time period without unreasonable effort and expense. The Company requires additional time to complete its management review of the Company’s quarter end consolidated financial statements and related disclosures. The Company currently expects to file the Form 10-Q within the five-day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended. Forward-Looking Statements This Form 12b-25 contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, including statements regarding the Company’s expectations regarding the timing of filing its Form 10-Q on or before the fifth day following its prescribed due date (the “extension deadline”), the consistency of the financial statements in the Form 10-Q with the financial information in the earnings release and the completion of matters necessary to permit filing by the extension deadline. Such forward-looking statements are based on assumptions about many important factors that could cause actual results to differ materially from those in the forward-looking statements, including whether the Company will identify additional errors in previously issued financial statements and other risks identified in the Company’s most recent filing on Form 10-K and other SEC filings, all of which are available on the Company’s website. The Company can provide no assurance that these forward-looking statements will be achieved, and actual results could differ materially from those suggested by such forward-looking statements. The Company does not undertake to update its forward-looking statements unless otherwise required by the federal securities laws
2025-04-07auditor changed or resigned SEC →
2023-12-22auditor changed or resigned SEC →
The Registrant has been unable, without unreasonable effort or expense, to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 due to delays in compiling the necessary financial information required to prepare a complete filing. The Quarterly Report will be filed within the extension period of the fifth calendar day following the prescribed due date
2022-12-13auditor changed or resignednot counted — change of control SEC →
Larkspur Health Acquisition Corp.’s (the “Company”) Annual Report on Form 10-K for the year ended December 31, 2021 cannot be filed within the prescribed time period because additional time is required to complete the review of its audited financial statements. The Company expects that its Annual Report on Form 10-K for the year ended December 31, 2021 will be filed on or before the 15th calendar day following the prescribed due date
reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.
Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.
See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.Every item above is a filing this company
made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not
investment advice